VIEWPOINT MOLECULAR TARGETING, INC. — Department of Health and Human Services SBIR Phase II: NCI
VIEWPOINT MOLECULAR TARGETING, INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,944,651
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NCI
- NAICS
- —
- Place of performance
- IA
- Period
- —
Description
Melanoma is one of the fastest growing cancer incidences in the world Disease detected early can be cured by surgery but metastatic melanoma is lethal Recent blockbusters extend life but response is low resistance develops almost invariably y survival and side effects can be severe Our Phase I RandD demonstrated the feasibility of our systemic targeted radionuclide therapy for metastatic melanoma In this Phase II project innovations to systemic targeted radionuclide therapy for melanoma developed in Phase I are optimized Achieving three Objectives will provide data needed to design pharmcology toxicology studies and an IND application to the FDA for human trials